Erasca, Inc. Cash Flow Breakdown
Cash flow breakdown shows where Erasca, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.
- Fiscal year ended 2025-12-31: from running the business, $95.45M went out.
- Fiscal year ended 2025-12-31: from investing, $100.42M came in.
- Fiscal year ended 2025-12-31: from financing, $1.10M came in.
- Fiscal year ended 2025-12-31: change in cash, $6.07M came in.
A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.
Each year (12 month)
| Fiscal year end | Running the business | From investing | New shares sold | Not split out | Change in cash |
|---|
| 2025-12-31 | -$95.45M | $100.42M | $372.00K | $724.00K* | $6.07M |
|---|
| 2024-12-31 | -$109.42M | -$156.62M | $836.00K | $239.86M* | -$25.34M |
|---|
| 2023-12-31 | -$101.22M | -$91.22M | $505.00K | $790.00K* | -$191.14M |
|---|
| 2022-12-31 | -$103.26M | -$71.08M | $95.25M | $2.82M* | -$76.27M |
|---|
| 2021-12-31 | -$79.60M | -$64.59M | $1.39M | $438.01M* | $295.21M |
|---|
| 2020-12-31 | -$32.69M | -$71.20M | $3.02M | $136.97M* | $36.10M |
|---|
Each quarter (3 month)
| Quarter end | Running the business | From investing | New shares sold | Not split out | Change in cash |
|---|
| 2026-06-30 | -$27.27M* | $19.49M* | $0.00* | $3.06M* | |
|---|
| 2026-03-31 | -$27.38M | -$243.83M | $258.75M | -$14.09M* | -$26.55M |
|---|
| 2025-12-31 | -$21.71M* | $24.71M* | $255.00K* | | |
|---|
| 2025-09-30 | -$21.66M* | $25.70M* | $41.00K* | | |
|---|
| 2025-06-30 | -$20.53M* | $15.74M* | $43.00K* | | |
|---|
| 2025-03-31 | -$31.55M | $34.27M | $33.00K | | $2.74M |
|---|
| 2024-12-31 | -$24.56M* | $22.62M* | $396.00K* | | |
|---|
| 2024-09-30 | -$22.42M* | -$102.59M* | $311.00K* | $20.79M* | |
|---|
| 2024-06-30 | -$29.18M* | -$86.61M* | $105.00K* | $211.76M* | |
|---|
| 2024-03-31 | -$33.25M | $9.97M | $24.00K | $6.91M* | -$16.35M |
|---|
| 2023-12-31 | -$24.79M* | $4.54M* | $193.00K* | | |
|---|
| 2023-09-30 | -$24.12M* | -$1.81M* | $7.00K* | | |
|---|
| 2023-06-30 | -$25.95M* | -$108.67M* | $122.00K* | $527.00K* | |
|---|
| 2023-03-31 | -$26.36M | $14.71M | $183.00K | | -$11.46M |
|---|
| 2022-12-31 | -$26.37M* | -$4.87M* | $742.00K* | $95.45M* | |
|---|
| 2022-09-30 | -$23.95M* | -$55.23M* | $427.00K* | | |
|---|
| 2022-06-30 | -$27.14M* | -$9.19M* | $375.00K* | $617.00K* | |
|---|
| 2022-03-31 | -$25.81M | -$1.79M | $460.00K | | -$27.14M |
|---|
| 2021-12-31 | -$22.48M* | -$63.95M* | $40.00K* | $1.07M* | |
|---|
| 2021-09-30 | -$23.22M* | -$4.94M* | $21.00K* | $317.55M* | |
|---|
| 2021-06-30 | -$18.23M* | $4.46M* | $180.00K* | | |
|---|
| 2021-03-31 | -$15.67M | -$162.00K | $1.14M | $119.39M* | $104.71M |
|---|
| 2020-12-31 | -$13.10M* | $16.57M* | -$112.00K* | | |
|---|
| 2020-09-30 | -$7.48M* | -$49.15M* | $2.64M* | $11.97M* | |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|